MedTrace Logo

Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT04777734 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-03-24

No results posted yet for this study

Summary

The aim of the Pre-Approval Access program is to provide efgartigimod PH20 SC treatment to patients with CIDP who are ineligible to participate in a clinical study and have unmet medical need despite available treatment options. The program will continue until the patient discontinues treatment or until the reimbursement process for CIDP concludes, whichever comes first.

Conditions

  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • CIDP

Interventions

BIOLOGICAL

Efgartigimod PH20 SC

Subcutaneous administration of Efgartigimod PH20 (via vial or prefilled syringe)

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04777734 on ClinicalTrials.gov